A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 Photoimmunotherapy Versus Physician’s Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of Therapy, of Which at Least One Line Must be Systemic Therapy

April 26, 2019
Cancer - Head and Neck
Principal Investigator: Steven S Chang, MD


ASP-1929 Photoimmunotherapy, Head and Neck Squamous Cell Carcinoma

Accepting Participants